Publications by authors named "Stephan Oertel"

Claim this Profile
F
Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.
Heiner Zimmermann, Theresa Weiland, Jamie P Nourse, Maher K Gandhi, Petra Reinke, Stephan Oertel

J Immunol Res· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study.
Mathias Witzens-Harig, Robin Foá, Alice Di Rocco, Guy van Hazel, Dalton F A Chamone, Stephan Oertel

Ann Hematol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.
Peter Hillmen, John G Gribben, George A Follows, Donald Milligan, Hazem A Sayala, Stephan Oertel

J Clin Oncol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Heiner Zimmermann, Petra Reinke, Ruth Neuhaus, Hans Lehmkuhl, Stephan Oertel

Cancer· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Ralf Trappe, Stephan Oertel, Veronique Leblond, Peter Mollee, Monica Sender

Lancet Oncol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report.
Isrid Sturm, Joachim Oertel, Stephan Oertel, Jörg Westermann, Antonio Pezzutto

J Med Case Rep· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
Ralf U Trappe, Sylvain Choquet, Petra Reinke, Martin Dreyling, Hans-Günther Mergenthaler, Stephan Oertel

Transplantation· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.
Sylvain Choquet, Stephan Oertel, Veronique LeBlond, Hanno Riess, Nathalie Varoqueaux

Ann Hematol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients.
Nina Babel, Athanasios Vergopoulos, Ralf Ulrich Trappe, Stephan Oertel, Markus H Hammer

Transplantation· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
Kathrin Sebelin-Wulf, Tuan D Nguyen, Stephan Oertel, Matthias Papp-Vary, Ralf Ulrich Trappe

Transpl Immunol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Ralf Trappe, Hanno Riess, Nina Babel, Manfred Hummel, Hans Lehmkuhl, Stephan Oertel

Transplantation· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.
Sylvain Choquet, Ralf Trappe, Veronique Leblond, Ulrich Jäger, Frederic Davi, Stephan Oertel

Haematologica· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.
Marion Subklewe, René Marquis, Sylvain Choquet, Veronique Leblond, Jeanne-Luce Garnier, Stephan Oertel

Transplantation· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Stephan Oertel, Ralf Ulrich Trappe, Kristin Zeidler, Nina Babel, Petra Reinke

Ann Hematol· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms' tumor and a novel alteration in intron 1 of the WT1 gene.
Ralf Ulrich Trappe, Hanno Riess, Frank Lippek, Michail Plotkin, Valerie Schumacher, Stephan Oertel

J Pediatr Hematol Oncol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Salvage chemotherapy for refractory or relapsed post-transplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide.
Stephan H Oertel, Matthias Papp-Váry, Ioannis Anagnostopoulos, Manfred W Hummel, Sven Jonas

Br J Haematol· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of early antigen BZLF1/ZEBRA protein of Epstein-Barr virus can predict the effectiveness of antiviral treatment in patients with post-transplant lymphoproliferative disease.
Stephan H Oertel, Ioannis Anagnostopoulos, Manfred W Hummel, Sven Jonas, Hanno B Riess

Br J Haematol· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunosurveillance, immunodeficiency and lymphoproliferations.
Stephan H Oertel, Hanno Riess

Recent Results Cancer Res· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations.
Stephan H Oertel, Hanno Riess

Recent Results Cancer Res· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis